TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Status:
Active, not recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This trial is a multi-center, single-arm phase 2 study to evaluate the efficacy and safety of
TJ202 combined with dexamethasone in subjects with relapsed or refractory multiple myeloma
(RRMM) who received at least 2 prior lines of treatment.